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osting by EAbstract A simple, sensitive and rapid chromatographic method was developed and validated for
the simultaneous quantiﬁcation of atenolol and chlorthalidone in human plasma using hydrochlo-
rothiazide as internal standard (IS). The method utilized proteins precipitation with acetonitril as
the only sample preparation involved prior to reverse phase-HPLC. The analytes were chromato-
graphed on Shim-pack cyanopropyl column with isocratic elution with 10 mM KH2PO4 (pH 6.0)
– methanol (70:30, v/v) at ambient temperature with ﬂow rate of 1 mL min1 and UV detection
at 225 nm. The chromatographic run time was less than 10 min for the mixture. The calibration
curves were linear over the range of 0.1–10 lg mL1. The method was validated in terms of accu-
racy, precision, absolute recovery, freeze–thaw stability, bench-top stability and re-injection repro-
ducibility. The within- and between-day accuracy and precision were found to be within acceptable
limits <15%. The analytes were stable after three freeze–thaw cycles (deviation <15%). The pro-
posed method was speciﬁc for the simultaneous determination of atenolol and chlorthalidone in
human plasma where there was no interference from endogenous biological substances.
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lsevier1. Introduction
Atenolol is a b1-selective b-adrenergic receptor-blocking agent
and clinically used for the treatment of hypertension. Like
other antihypertensive drugs, atenolol lowers the systolic and
diastolic blood pressure by 15–20% in a single drug treatment
and reduces cardiovascular mortality. It is also used alone or
in combination with other antihypertensive agents for the
treatment of myocardial infraction, arrhythmias, angina and
disorders arising from decreased circulation and vascular con-
striction, including migraine (Prichard et al., 2001; Wadworth
et al., 1991). Atenolol is rapidly but incompletely absorbed
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changed drug, 35–50% of an oral dose being excreted in the
urine and 30–50% in the faeces in 24 h. After a single oral dose
of 100 mg given to 12 subjects, peak plasma concentrations of
0.41–0.87 mg1 L (mean 0.6) were attained in about 3 h (Mof-
fat et al., 2004).
Chlorthalidone is a diuretic drug widely used in hyperten-
sion therapy. This sulphonzunide-like diuretic differs chemi-
cally from the thiazides by the nature of the heterocyclic
ring, although its pharmacological action is indistinguishable
from that of the thiazides (Thomson, 1970). Chlorthalidone
is readily but incompletely absorbed after oral administration.
It does not appear to be signiﬁcantly metabolized. After a sin-
gle dose, about 25–40% is excreted in the urine as unchanged
drug and about 1% is eliminated in the bile; the quantity ex-
creted in the urine appears to be dose-dependent. During daily
therapy, about 50% of the daily dose is excreted unchanged in
the urine in 24 h and about 25% is eliminated in the faeces.
After single oral doses of 50–75 mg given to 7 subjects, peak
plasma concentrations of 0.14–0.26 mg/L were attained in 1–
3 h (Moffat et al., 2004).
In recent years, pharmaceutical preparations containing
both drugs have also been marketed, their combination having
the advantage of providing greater therapeutic effects than
with either drug alone or permitting once a day administration
only, the two drugs not interacting pharmacokinetically with
each other or presenting synergic toxic effects. The two drugs
are of limited metabolism and eliminated unchanged from hu-
man body (Sweetman, 2006).
In open literature, several methods have been reported for
the determination of atenolol in biological ﬂuids that relied
on HPLC with UV or ﬂuorimetric detection (Guadrado
et al., 2002; Martins et al., 1997; Niopas et al., 2000; Ranta
et al., 2002; Wu et al., 2003), HPLC with MS detection (Dong
and Huang, 2006; Johnson and Lewis, 2006; Dupuis et al.,
2004), and adopting gas chromatographic techniques with an
electron capture detector (Malluca and Monson, 1975; Wan
et al., 1978).
On the other hand, chlorthalidone has been measured in
biological ﬂuid both by GC and nitrogen detection (Degen
and Schweizer, 1977; Ervik and Gustavii, 1974), HPLC using
analogous columns and UV detection (Dadgar and Kelly,
1988; Muirhead and Christie, 1987), or HPLC coupled with
MS detector (Yu et al., 2005; Goebel et al., 2004). The previ-
ously reported methods applied liquid-liquid extraction or so-
lid phase extraction as the main technique and there is no
method applied for protein precipitation technique for their
determination in biological ﬂuids.
Atenolol and chlorthalidone mixture is ofﬁcially listed in
USP. To our knowledge, there are many methods that have
been published for simultaneous determination of both drugs
in pharmaceutical formulations like chemometric-assisted
spectophotometic (Ferraro et al., 2003; Mohamed and Salem,
2005; El-Gindy et al., 2005) and HPLC with UV detection (El-
Gindy et al., 2005). These methods were not suitable for simul-
taneous determination of the proposed mixtures in biological
ﬂuids due to matrix interference. Recently our laboratory ap-
plied chromatographic technique for simultaneous determina-
tion of ternary mixtures for hypertension treatment containing
the two studied drugs (Elshanawane et al., 2009). This method
failed to quantitate the studied mixture in plasma because of
the short retention time of atenolol that interfered with plasmamatrix (Elshanawane et al., 2009). Additionally there are two
methods that have been described for simultaneous determina-
tion of both drugs in human milk (El-Gindy et al., 2008) and
plasma (Giachetti et al., 1997). These methods required long
time for preparation of samples or relied on tedious liquid-li-
quid extraction procedure. Therefore, it was desirable to devel-
op simple, accurate, and fast procedure that could be applied
for the simultaneous determination of atenolol and chlorthal-
idone in plasma after protein precipitation as the only sample
preparation step involved prior to reversed phase-HPLC.2. Experimental
2.1. Chemicals and reagents
Atenolol (Almirall prodes farma, Spain, 99.8%), Chlorthali-
done (Channgzhou Zinhua Chemical product Co. Limited,
China, 99.85), and hydrochlorothiazide (IS) (Aurbindo Ltd.,
Ireland, 99.9%) were used. Methanol and acetonitril (HPLC
grade) were purchase from (Riedel-de Haen laboratory chem-
icals, Germany). Potassium dihydrogen phosphate, phosphoric
acid, and NaOH (Sigma–Aldrich, Inc., St. Louis, USA) used
were of analytical grade. Double distilled water was used
throughout the study.
2.2. Equipment
The HPLC (Shimadzu, Kyoto, Japan) instrument was
equipped with a model series LC-10 ADVP pump, SCL-10
AVP system controller, DGU-12 A Degasser, Rheodyne
7725i injector with a 20 lL loop and a SPD-10AVP UV–VIS
detector. The sample was injected with 25 lL Hamilton analyt-
ical syringe. Data acquisition was performed on Class-VP soft-
ware (version 6).
2.3. Chromatographic condition
The HPLC separation and quantitation were achieved on a
250 · 4.6 mm (I.d) Shim-pack (5 lm particle size) cyanopro-
pyl column (Shimadzu, Kyoto, Japan). The mobile phase was
prepared by mixing 10 mM KH2PO4 (pH 6.0) – methanol
(70:30, v/v) that run isocratically at ﬂow rate 1 mL min1.
All determinations were performed at ambient temperature.
The injected volume was 20 lL. The detector was set at k
225 nm.
2.4. Preparation of standard and quality control samples
Stock standard solutions of the studied drugs in the two mix-
tures (1 mg mL1) were separately prepared in methanol.
Working solutions were prepared by appropriate dilution in
methanol just before use. All solutions were stored in darkness
at 4 C. Volumes of 20 lL of the preparing working solutions
and 20 lL of IS solution (150 lg mL1) were added to 960 lL
of drug-free human plasma to obtain drug concentration levels
of 0.1, 0.2, 0.6, 1.0, 2.0, 5.0, 7.0, and 10 lg mL1. Quality con-
trol (QC) samples were prepared separately and pooled at
three different concentration levels (0.1, 1, 10.0 lg mL1) as
low, medium and high, respectively. The samples were stored
in a freezer at 20 C until analysis. A calibration curve was
constructed from a blank sample (a plasma sample processed
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and eight non-zero samples covering the total range of 0.1–
10.0 lg mL1, including the LOQ. Calibration curves were
generated using the analytes to IS peak area ratios by least-
squares linear regression.
2.5. Sample preparation
The stored plasma samples were thawed at room temperature
before processing. The plasma samples were centrifuged at
4000 rpm for 10 min. An aliquot (1.0 mL) was pipetted into
a 10 mL polypropylene tube and acetonitril (2.0 mL) was
added. The mixture was vortex mixed brieﬂy, and after stand-
ing for 5 min at room temperature, the mixture was centri-
fuged at 4000 rpm for 20 min and the supernatant (20 lL)
was injected into HPLC system.
2.6. Validation of the bioanalytical method
The method was validated by the determination of the follow-
ing parameters: speciﬁcity, linearity, range, recovery, accuracy,
precision, lower limit of quantitation (LLOQ), and stability
studies according to the currently accepted US food drug
administration (FDA) bioanalytical method validation guid-
ance (US Department of Health and Human Services, 2001).
2.7. Speciﬁcity
Randomly selected six blank human plasma samples, which
were collected under controlled conditions, were carried
through the protein precipitation procedure and chromato-
graphed individually to determine the extent to which endoge-
nous plasma components could contribute to interference with
the analyte or the internal standard.
2.8. Calibration curve
The calibration curves were constructed from a blank sample
(a plasma sample processed without IS), a zero sample (a plas-
ma processed with IS), and eight concentrations of the studied
drugs including the LLOQ, ranging from 0.1 to 10 lg mL1.
The peak area ratio of the drug to the IS against the respective
standard concentrations was used for plotting the graph and
the linearity evaluated by a least squares regression analysis.
2.9. Recovery
The analytical recovery was calculated by comparing chro-
matographic peak areas from standard samples prepared
post-extracted blank plasma and from standard spiked sam-
ples at three different concentrations (0.1, 1, 10.0 lg mL1)
for the studied drugs.
2.10. Accuracy and precision
To evaluate the inter-day precision and accuracy, the quality
control samples were for 3 consecutive days, while intra-day
precision and accuracy were evaluated through analysis of val-
idation control samples at three different concentrations in six
replicates in the same day. Inter- and intra-day precision was
expressed as relative standard deviation (RSD). The accuracy
was expressed as the relative error (RE) for the determinationof the studied drugs in each human plasma sample. The eval-
uation of precision was based on the criteria (US Department
of Health and Human Services, 2001) that the deviation of
each concentration level should be within ±15%, except for
the LLOQ, for which it should be within ±20%. Similarly
for accuracy, the mean value should not deviate by ±15%
of the nominal concentration, except the LLOQ, where it
should not deviate by ±20% of the nominal concentration.
2.11. Lower limit of quantiﬁcation (LLOQ) and limit of
detection (LOD)
Lowest standard concentration on the calibration curve should
be accepted as the limit of quantiﬁcation if the following con-
ditions are met: the analyte response at the LLOQ should be at
least ﬁve times the response compared to blank response and
analyte peak (response) should be identiﬁable, discrete, and
reproducible with a precision of 20% and accuracy of 80–
120%. The limit of detection (LOD) was deﬁned by the con-
centration with a signal-to-noise ratio of 3.
2.12. Stability
The concentration of the studied drugs after each storage per-
iod was related to the initial concentration as zero cycle (sam-
ples that were freshly prepared and processed immediately).
The samples were considered stable if the standard deviation
(expressed as percentage bias) from the zero cycle was within
+15%.
2.12.1. Freeze–thaw stability
The freeze–thaw stability of the studied drugs was determined at
low, medium, and high QC samples (n= 3), over three freeze–
thaw cycles within 3 days. In each cycle, the frozen plasma sam-
ples were thawed at room temperature for 2 h and refrozen for
24 h. After completion of each cycle the samples were analyzed
and the results were compared with that of zero cycle.
2.12.2. Short-term stability (bench-top stability)
Three aliquots each of the low, medium, and high unprocessed
QC samples were kept at room temperature for 24 h. After
24 h the samples were analyzed and the results were compared
with that of zero cycle.
2.12.3. Long-term stability
Three aliquots each of the low, medium, and high QC samples
were frozen at 20 C for 30 days. The samples were analyzed
and the results were compared with that of zero cycle.3. Results and discussion
To obtain the best chromatographic condition, different col-
umns like C18, C8, and CN-propyl and mobile phases com-
posed of buffer system like phosphate and acetate and other
with different pH ranged from 2 to 7 and organic modiﬁer like
methanol and acetonitril were tested to provide sufﬁcient selec-
tivity and sensitivity in short separation time. The best chro-
matographic separation occurred on cyanopropyl column
with a mobile phase consisting of 10 mM KH2PO4 (pH 6.0)
– methanol (70:30, v/v) at a ﬂow rate of 1 mL min1 and UV
detection at 225 nm (Figs. 1 and 2).
Figure 1 HPLC chromatogram of 20 lL injection of human
blank plasma samples.
Figure 2 HPLC chromatogram of 20 lL injection of atenolol
(ATE), chlorthalidone (CHL), and hydrochlorothiazide (HYD) as
IS spiked in human plasma.
Figure 3 HPLC chromatogram of 20 lL injection of patient
plasma sample, 4 h following oral administration of Bolkium
Diu tablet (100 mg atenolol + 25 mg chlorthalidone).
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tration and pH was carefully studied. Increasing organic mod-
iﬁer concentration not only improves peak shape and
decreasing the run time but also decreasing method speciﬁcity
due to the interference of the atenolol peak with endogenous
biological substance. Decreasing of organic modiﬁer concen-
tration below 20% resulted in high speciﬁcity with regard to
the separation of the studied drugs from endogenous biological
substances, and more retained of the drug on the column that
led to excessive tailing of eluting peaks and long run time.Variation of pH played an important role in the separation
process. At pH (<3.5), atenolol became more retained on the
column and eluted with some degree of overlapping with
hydrochlorothiazide (IS). At pH (3.5–5.0) good resolution
was obtained with better peak shape for the three drugs but
atenolol was eluted interfering with endogenous biological
substances. pH (6.0) was chosen as the optimum value both
for the resolution of the drugs from endogenous biological
substances and better peak shape and reasonable run time
(<10 min).
Hydrochlorothiazide was considered as best (IS) applied for
determination of atenolol and chlorthalidone when compared
to other substances such as paracetamol, caffeine, theopylline
and guaifensine owing to retention characters that are not af-
fected seriously by change of pH, therefore, it was eluted with
reasonable resolution from atenolol and chlorthalidone, and
absorbance characters that show high absorbance at the cho-
sen wavelength (225 nm) that increase the sensitivity of the
method.
The proposed method succeeds in the determination of the
studied mixture in spiked plasma sample and also in real pa-
tient plasma sample, 4 h following oral administration of Bolk-
ium Diu tablet (100 mg atenolol and 25 mg chlorthalidone)
(Figs. 2 and 3).4. Validation of the proposed method
4.1. Speciﬁcity and selectivity
Before the preparation of the pooled calibration standards and
QC samples, six lots of blank plasma were screened for matrix
effects or interferences. The interference from individual blank
plasma in the LC-UV chromatograms at the retention times of
the studied drug and IS with or without both drugs and IS was
investigated to ensure the speciﬁcity of the method. Each sam-
ple of six blank plasmas was eluted three times individually
and they found to be free of co-eluting peaks at the retention
time range of drugs and IS (Fig. 1).
Table 1 Assay parameters and regression characteristic aten-
olol and chlorthalidone determined by the proposed HPLC
method.
Parameters Atenolol Chlorthalidone
Linearity range (lg mL1) 0.1–10 0.1-10
Detection limit (lg mL1) 0.06 0.038
Quantitation limit (lg mL1) 0.2 0.129
Regression equation (y*)
Number of experiments (n) 8 8
Slope (b) 0.189 0.529
Standard deviation of slope 0.005 0.0091
Relative standard deviation of slope 2.64 1.7
Intercept (a) 0.0524 0.022
Standard deviation of intercept 0.026 0.0365
Correlation coeﬃcient (r) 0.998 0.9991
Standard error of regression 0.048 0.084
* Y = a+ bC, where C is the concentration (ug/mL) and Y is the
peak area.
Table 2 Recovery of atenolol and chlorthalidone from
plasma determined by the proposed HPLC method.
Concentration
(lg mL1)
Recovery % (mean ± RSD)
Atenolol Chlorthalidone
0.1 94.54 ± 7.21 93.12 ± 6.4
1 95.3 ± 4.1 98.47 ± 5.7
10 98.24 ± 6.8 94.01 ± 3.5
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quantitation
During prestudy validation, the calibration curves were de-
ﬁned in three runs based on triplicate assays of the spiked
blank plasma samples. The regression parameters of slope,
intercept and correlation coefﬁcient were calculated by a
least-squares linear-regression analysis (Table 1). Good
linearity was obtained over the concentration range of 0.1–
10 lg mL1. A typical linear regression equation, the lower
limit of quantitation (LLOQ) and limit of detection (LD)
and other parameters for the determination of atenolol and
chlorthalidone in human plasma were listed in Table 1. The
linearity of calibration curves was validated by the high valueTable 3 Intra- and inter-day precision and accuracy for the determ
Add concentration
(lg mL1)
Intra-day Inter-day
0.1 1 10 1st day
0.1 1
Atenolol
Mean 0.098 1.06 9.89 0.092 0.983
SD 0.006 0.058 0.321 0.003 0.062
RSD % 6.122 5.472 3.246 3.261 6.307
RE % 2 6 1.1 8 1.7
Chlorthalidone
Mean 0.0924 0.958 10.21 0.102 1.043
SD 0.005 0.018 0.27 0.004 1.04
RSD % 5.411 1.879 2.644 3.922 1.04
RE % 7.6 4.2 2.1 2 1.04of correlation coefﬁcient and the intercept value, which was
not statistically (P= 0.05) different from zero (Table 1).
4.3. Recovery
The absolute recoveries of the studied drugs were determined
by comparing the peak area ratio of the QC sample spiked
in human plasma and deﬁned in three runs with those of post
extracted plasma blanks fortiﬁed with the known amount of
analytes. The results in Table 2 indicate high ability of the pro-
posed method to recover the studied drugs from human
plasma.
4.4. Precision and accuracy
The precision and accuracy of the method were assessed by
analyzing six replicate QC samples at the low, medium and
high concentration levels. The accuracy of the method was
determined by calculating relative error (RE) and the precision
by calculating RSD. Table 3 summarizes the precision and
accuracy on each of three assays for two drugs in human
plasma with accuracy ranging from 8% to 6.2% (RE) of
nominated values and the precision ranging from 0.236% to
6.5% (RSD) over the three concentration levels evaluated.
4.5. Stability
The stability of the studied drugs in human plasma was assessed
by analyzing six replicate QC samples at the low, medium and
high concentration levels at ambient temperature over 24 h
(bench top stability). The measured concentrations of the drugs
in these QC samples sitting at room temperature for 24 h were
compared with that obtained with the corresponding QC
sample freshly prepared and proceed immediately. The results
in table indicate that the studied drugs were stable for at least
24 h in human plasma when stored at ambient temperature.
On the other hand, QC samples experiencing three freeze–thaw
cycles (freeze–thaw stability) were analyzed together. The re-
sults indicate the stability of the studied drug in human plasma
over three freeze–thaw cycles (Table 4). Also the studied drug
showed the stability in human plasma when stored at 20 C
for one month (where the whole samples were frozen, thawed
and completely analyzed as mentioned) as long term stability
when compared with the freshly prepared sample.ination of atenolol and chlorthalidone in human plasma.
2nd day 3rd day
10 0.1 1 10 0.1 1 10
9.75 0.102 0.968 10.14 0.107 0.983 10.24
0.45 0.006 0.04 0.371 0.007 0.052 0.54
4.615 5.882 4.132 3.659 6.542 5.290 5.273
2.5 2 3.2 1.4 7 1.7 2.4
10.14 0.1062 0.984 9.75 0.0985 1.04 9.56
0.54 0.007 0.035 0.023 0.002 0.028 0.121
5.325 6.591 3.557 0.236 2.030 2.692 1.266
1.4 6.2 1.6 2.5 1.5 4 4.4
Table 4 Summary of stability of atenolol and chlorthalidone in human plasma at varying condition.
Add concentration (lg mL1) Theoretical concentration
Atenolol Chlorthalidone
0.1 1 10 0.1 1 10
(a) Three freeze–thaw cycles
Mean 0.0924 1.07 10.17 0.0991 0.955 10.32
SD 0.003 0.104 0.26 0.01 0.081 0.331
RSD % 3.2468 9.7196 2.5565 10.091 8.4817 3.2074
RE % 7.6 7 1.7 0.9 4.5 3.2
(b) Room temperature for 24 h
Mean 0,0891 1.04 10.04 0.0954 1.075 9.56
SD 0.004 0.12 0.171 0.005 0.054 0.231
RSD % 4.4893 11.538 1.7032 5.2411 5.0233 2.4163
RE % 10.9 4 0.4 4.6 7.5 4.4
(c) Re-injection after 30 day at 20 C
Mean 0,091 1.113 10.22 0.0964 0.987 10.05
SD 0.008 0.176 0.251 0.008 0.107 0.075
RSD % 8.7912 15.813 2.456 8.2988 10.841 0.7463
RE % 9 11.3 2.2 3.6 1.3 0.5
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methods
When comparing between the proposed method and the pub-
lished methods for simultaneous determination of the binary
mixture (Elshanawane et al., 2009; El-Gindy et al., 2008;
Giachetti et al., 1997) found that:
 The suggested method is highly selective when compared to
our previous method that failed to separate atenolol from
plasma matrix (Elshanawane et al., 2009).
 The proposed method utilizes proteins precipitation with
acetonitril as the only sample preparation involved prior
to reverse phase-HPLC rather than the other method that
requiring many steps before injection (El-Gindy et al.,
2008) or depending on liquid-liquid extraction that need
long time and effort for sample preparation before injec-
tion, and also the possibility of drug lost during preparation
is high (Giachetti et al., 1997).
 The run time of the proposed method is short when com-
pared to the published method (Giachetti et al., 1997) that
needs 20 min to elute the two drugs.5. Conclusion
The method developed is a simple, rapid, accurate, and reliable
procedure for the analysis of atenolol and chlorthalidone in
human plasma, meeting all requirements for the validation
of an analytical methodology. It is adequate to monitor pa-
tients receiving therapeutic dosage of the drugs.
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